Compare VANI & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VANI | HLN |
|---|---|---|
| Founded | 1998 | 2022 |
| Country | United States | United Kingdom |
| Employees | 36 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.0M | 43.7B |
| IPO Year | 2014 | N/A |
| Metric | VANI | HLN |
|---|---|---|
| Price | $1.17 | $8.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | 294.8K | ★ 8.5M |
| Earning Date | 05-14-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,000,000.00 | N/A |
| Revenue This Year | N/A | $6.55 |
| Revenue Next Year | N/A | $4.42 |
| P/E Ratio | ★ N/A | $49.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $8.71 |
| 52 Week High | $1.92 | $11.42 |
| Indicator | VANI | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 34.64 |
| Support Level | $1.08 | $8.74 |
| Resistance Level | $1.55 | $10.03 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 18.52 | 10.53 |
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.